Plérixafor (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 285 | ファンコニ貧血 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-005264-14-FR (EUCTR) | 19/06/2015 | FancoMob: Pilote study for a combined treatment helping to collect stem cells in patient suffering Fanconi anemia | NA - EUROFANCOLEN | Fanconi Anemia MedDRA version: 18.1;Level: LLT;Classification code 10055206;Term: Fanconi's anemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Zarzio Product Name: Zarzio INN or Proposed INN: filgrastim Other descriptive name: G-CSF Trade Name: Mozobil Product Name: Mozobil INN or Proposed INN: plérixafor | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | NA | Female: yes Male: yes | Phase 2 | France |